The goal of this clinical trial is to learn if GNSC-001 works to treat knee osteoarthritis in adults. It will also learn about the safety of GNSC-001. The main questions it aims to answer are: 1. Does GNSC-001 lower daily knee joint pain and improve function in participants? 2. What medical problems do participants have when taking GNSC-001? Researchers will compare GNSC-001 to a placebo (a look-alike substance that contains no drug) to see if GNSC-001 works to treat knee osteoarthritis. Participants will: 1. Receive a single injection of immune-modulation, and GNSC-001 or a placebo, in their knee 2. Take an oral immune-modulating pill every day for the first 22 days 3. Visit the clinic at least 9 times over 2 years for checkups and tests 4. Keep a diary of their symptoms and the number of times they use a rescue medication
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
240
Single intra-articular injection into target knee
Single intra-articular injection into target knee
Change from baseline in OA pain as assessed by the Weekly Average of Daily Pain (WADP) Numeric Rating Scale (NRS) at Week 52
Time frame: Baseline and Week 52
Change from baseline in the function subscale of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) at Week 52
Time frame: Baseline and Week 52
Incidence and severity of treatment emergent adverse events (TEAEs), events of clinical interest (ECIs), and serious adverse events (SAEs)
Time frame: From enrollment to the end of study at 104 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.